So when the companyannounced on Friday morning that it was making a significant change to its late-stage clinical study of obeticholic acid in treating NASH, investors were eager to find out what’s going on. Intercept’s phase 3 REGENERATE clinical trial initially had two co-primary endpoints: fibrosis improvement with no worsening of NASH and NASH resolution with no worsening of fibrosis.